Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Verona Pharma PLC
VRNAView Detailed Chart
65.460USD
+0.679+1.05%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
44.32BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.05%
5 Days
+11.10%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
10
analysts
BUY
Current Rating
80.300
Target Price
22.67%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
556
Total
5
Median
6
Average
Company name
Ratings
Analysts
Verona Pharma PLC
VRNA
10
CRISPR Therapeutics AG
CRSP
29
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Moderna Inc
MRNA
27
1
2
3
...
111
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
News
More news coming soon, stay tuned...
Company
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Company codeVRNA
CompanyVerona Pharma PLC
CEODr. David S. Zaccardelli
Websitehttps://www.veronapharma.com/
Related Instruments
Regeneron Pharmaceuticals Inc
+0.48%
argenx SE
+2.37%
IQVIA Holdings Inc
-0.27%
Biontech SE
-15.36%
Beigene Ltd
-4.40%
Summit Therapeutics Inc
+4.84%
Insmed Inc
+1.06%
ICON PLC
-0.66%
Exelixis Inc
+0.59%
Moderna Inc
-0.62%
Biodexa Pharmaceuticals PLC
+9.86%
Ascendis Pharma A/S
+2.31%
Qiagen NV
-2.26%
Medpace Holdings Inc
-1.43%
Tempus AI Inc
-1.12%
Exact Sciences Corp
-0.31%
Bio-Techne Corp
-1.06%
Revolution Medicines Inc
+0.49%
Legend Biotech Corp
+0.12%
Charles River Laboratories International Inc
-0.92%
